RNA medicines can target any gene or protein in humans and so can be used to treat diseases that cannot be treated by conventional drugs such as small molecules and biologics.
Our bodies and cells are made up of many different proteins. Diseases occur when genes and proteins inside our bodies malfunction. DNA contains the genetic code needed for cells to make proteins. Various types of RNA, including messenger RNA (mRNA), small interfering RNA (siRNA) and microRNA, work together to control how the genes contained in our DNA are translated into proteins.
Arcturus’ proprietary UNA Oligomer and LUNAR™ delivery technologies can be used to make all classes of RNA medicines safe and effective.
January 7, 2018
Arcturus Therapeutics to Present in a Panel Discussion at East/West CEO Conference Called “Challenges and Opportunities in Biotech” on Sunday, Jan 7th 2018, from 11:20 am - 11:50 am.
January 5, 2018
Johnson & Johnson Innovation Champions Leading Edge Science with 15 New Collaborations with Potential to Impact Patients' Lives
January 4, 2018
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics